Clinical trial
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel…
NCT00272987 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00272987 |
|---|---|
| Title | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib |
| Official title | A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib, paclitaxel, trastuzumab |
| Enrollment | 63 |
| Start date | Dec 13, 2005 |
| Primary completion | Jul 31, 2009 |
| Completion | Oct 21, 2019 |
| First posted | Jan 9, 2006 |
| Last update posted | Apr 28, 2023 |
| Countries | Belgium, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: